Pre-Exposure Prophylaxis (PrEP)
PrEP is antiretroviral medication taken by a person who is HIV negative to reduce the risk of contracting HIV. The Food and Drug Administration has approved the following three regimens for PrEP:
| DRUG: Truvada (tenofovir disoproxil fumarate + emtricitabine) | |
|---|---|
| ADULT DOSING INFO | One tablet once a day. For some people, taking PrEP “on demand” before and after sex may be an option. Each tablet contains 300 mg tenofovir disoproxil fumarate (TDF) + 200 mg emtricitabine. |
| APPROVED FOR | Approved for HIV-negative men, women and transgender individuals at risk for sexually acquired HIV. Generic version available. |
| DRUG CLASS | Nucleoside/ Nucleotide Reverse Transcriptase Inhibitors (NRTIs, or nukes) |
| DRUG: Descovy (tenofovir alafenamide + emtricitabine) | |
|---|---|
| ADULT DOSING INFO | One tablet once a day. Each tablet contains 25 mg tenofovir alafenamide (TAF) + 200 mg emtricitabine. |
| APPROVED FOR | Not approved for those at risk for HIV acquisition via vaginal sex. |
| DRUG CLASS | Nucleoside/ Nucleotide Reverse Transcriptase Inhibitors (NRTIs, or nukes) |
| DRUG: Apretude (cabotegravir) | |
|---|---|
| ADULT DOSING INFO | Apretude is given as a single injection in the buttocks by a health care worker every other month. Apretude is initiated with two 600 mg injections given one month apart for the first two months, after which injections are given every two months. Alternatively, oral cabotegravir (Vocabria) may be taken for four weeks before the injections. |
| APPROVED FOR | Approved for HIV-negative men, women and transgender individuals at risk for sexually acquired HIV. |
| DRUG CLASS | Integrase Inhibitors |
| DRUG: Yeztugo (lenacapavir) | |
|---|---|
| ADULT DOSING INFO | Yeztugo is initiated with two 463.5 mg subcutaneous injections and two 300 mg tablets on day 1 and two 300 mg tablets on day 2, after which two injections are given every six months |
| APPROVED FOR | Approved for adults and adolescents weighing at least 77 pounds at risk for sexually acquired HIV. |
| DRUG CLASS | Capsid inhibitor |
Post-Exposure Prophylaxis (PEP)
PEP involves taking a short course of antiretroviral drugs, usually for a month, after a high-risk exposure to HIV. For maximum effectiveness, PEP should be started immediately—and no more than 72 hours—after possible exposure. The Centers for Disease Control and Prevention (CDC) recommends the following regimens for PEP:
| DRUG: Biktarvy (bictegravir + tenofovir alafenamide + emtricitabine) | |
|---|---|
| DOSING INFO | One tablet once a day. Each tablet contains 50 mg bictegravir + 25 mg tenofovir alafenamide + 200 mg emtricitabine. |
OR A COMBINATION OF
| DRUG: Tivicay (dolutegravir) | |
|---|---|
| DOSING INFO | One tablet once a day. Each Tivicay tablet contains 50 mg dolutegravir. The Dovato combination pill contains 50 mg dolutegravir + 300 mg lamivudine. |
PLUS
| DRUG: Truvada (tenofovir disoproxil fumarate + emtricitabine) | |
|---|---|
| DOSING INFO | One tablet once a day. Each tablet contains 300 mg tenofovir disoproxil fumarate + 200 mg emtricitabine. Generic versions are available. |
OR
| DRUG: (tenofovir alafenamide + emtricitabine) | |
|---|---|
| DOSING INFO | One tablet once a day. Each tablet contains 25 mg tenofovir alafenamide + 200 mg emtricitabine. |
OR
| DRUG: tenofovir disoproxil fumarate + lamivudine | |
|---|---|
| DOSING INFO | One tablet of each drug once a day. Generic versions are available. |
Alternative PEP regimens can be found online in the Centers for Disease Control and Prevention’s PEP Guidelines.
Click here for a printable version of this drug chart.
Click here for more information on HIV prevention.
Comments
Comments